Abstract: The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.

Abstract: This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A1AT or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.

Abstract: This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A1AT or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.

Abstract: The present invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ rejection, transplantation-mediated transmission of viral infection, and triggering of apoptosis in transplanted tissues can each be minimized by the methods and compositions of the instant invention. The RNAi agent(s) of the instant invention can be delivered as “naked” molecules, or using liposomal and other modes of delivery, to transplantable tissues. Such delivery can occur via perfusion of the RNAi agent in solution through the vasculature of a whole or partial organ; or tissues including transplantable cells and cell lines may be bathed, injected or otherwise treated with RNAi agents. Preferred transplantable tissues include, for example, pancreas, liver, kidney, heart, lung, and all cells and cell lines derived from such tissues (e.g., pancreatic islet cells that may, e.g.